MediciNova, Inc. (MNOV)
Develops oral drugs to treat neurological disorders like multiple sclerosis and ALS.
$1.33+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-7.0%
The outlook
MNOV is trading near the lower end of its 52-week range, well below both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target implying substantial upside from current levels. The overall sentiment remains neutral as the stock reflects mixed technical positioning against optimistic analyst views.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +577% vs current price
Analyst price target
~12-month · 3 analysts$9.00average target+576.7% vs now
Now $1.33
Low $6.00High $11.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$65.5M
52-wk high
$1.96
52-wk low
$1.17
50-day avg
$1.35
200-day avg
$1.42
Trailing P/E
—